ClinicalTrials.Veeva

Menu
Willow Rheumatology and Wellness, PLLC | Willowbrook, IL logo

Willow Rheumatology and Wellness, PLLC | Willowbrook, IL

Research site

Site insights

Top conditions

Top treatments

Tirzepatide
Upadacitinib
Ixekizumab
Secukinumab
Ianalumab
Adalimumab
LY3541860
LY3871801
Guselkumab
JNJ-77242113

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Angela R. Crowley, MD, FACR

Verified by this site

Active trials

12 of 13 total trials

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The main purpose of this study is to evaluate the effects of LY3541860 in adult participants with moderately to severely active Rheumatoid Arthritis...

Enrolling
Rheumatoid Arthritis
Drug: LY3541860

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by ass...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Active reference comparator

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Overweight or Obesity
Psoriatic Arthritis
Drug: Tirzepatide

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid...

Enrolling
Rheumatoid Arthritis
Drug: LY3871801
Drug: Placebo

The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at leas...

Active, not recruiting
Obesity
Psoriatic Arthritis
Drug: Tirzepatide
Drug: Ixekizumab

The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (S...

Enrolling
Sjogrens Syndrome
Drug: Placebo
Drug: Standard of care treatment

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of...

Enrolling
Systemic Lupus Erythematosus
Drug: placebo
Drug: ianalumab
Locations recently updated

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the...

Enrolling
Autoimmunity, Inflammation
Biological: Secukinumab s.c. injection

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Active, not recruiting
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Device: Non-active stimulation

Trial sponsors

Lilly logo
Janssen (J&J Innovative Medicine) logo
Novartis logo
AbbVie logo
S

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems